Department of Critical Medicine, the Second Hospital of Lanzhou University, Lanzhou, 730030, China.
Department of Oncology, Gansu Provincial Hospital of Traditional Chinese Medicine, Lanzhou, 730030, China.
BMC Infect Dis. 2023 Jun 19;23(1):415. doi: 10.1186/s12879-023-08393-8.
Awake prone positioning has been widely used in non-intubated patients with acute hypoxic respiratory failure (AHRF) due to COVID-19, but the evidence is mostly from observational studies and low-quality randomized controlled trials (RCTs), with conflicting results from published studies. A systematic review of published high-quality RCTs to resolve the controversy over the efficacy and safety of awake prone positioning in non-intubated patients with AHRF due to COVID-19.
Candidate studies were identified through searches of PubMed, Web of Science, Cochrane, Embase, Scopus databases from December 1, 2019 to November 1, 2022. Literature screening, data extraction and risk of bias assessment were independently conducted by two researchers.
Eight RCTs involving 2657 patients were included. Meta-analysis of fixed effects models showed that awake prone positioning did not increase mortality(OR = 0.88, 95%CI [0.72, 1.08]), length of stay in ICU (WMD = 1.14, 95%CI [-0.45, 2.72]), total length of stay (WMD = 0.11, 95%CI [-1.02, 1.23]), or incidence of adverse events (OR = 1.02, 95%CI [0.79, 1.31]) compared with usual care, but significantly reduced the intubation rate (OR = 0.72, 95%CI [0.60, 0.86]). Similar results were found in a subgroup analysis of patients who received only high flow nasal cannula (Mortality: OR = 0.86, 95%CI [0.70, 1.05]; Intubation rate: OR = 0.69, 95%CI [0.58, 0.83]). All eight RCTs had high quality of evidence, which ensured the reliability of the meta-analysis results.
Awake prone positioning is safe and feasible in non-intubated patients with AHRF caused by COVID-19, and can significantly reduce the intubation rate. More studies are needed to explore standardized implementation strategies for the awake prone positioning.
CRD42023394113.
清醒俯卧位已广泛应用于因 COVID-19 导致的急性低氧性呼吸衰竭(AHRF)的非插管患者,但证据主要来自观察性研究和低质量的随机对照试验(RCT),且已发表的研究结果相互矛盾。本系统评价旨在通过对已发表的高质量 RCT 进行综述,以解决 COVID-19 所致 AHRF 非插管患者清醒俯卧位治疗的疗效和安全性方面的争议。
通过检索 PubMed、Web of Science、Cochrane、Embase 和 Scopus 数据库,于 2019 年 12 月 1 日至 2022 年 11 月 1 日确定候选研究。由两名研究人员独立进行文献筛选、数据提取和偏倚风险评估。
纳入 8 项 RCT,共 2657 例患者。固定效应模型的荟萃分析结果显示,与常规护理相比,清醒俯卧位并未增加死亡率(OR=0.88,95%CI [0.72, 1.08])、ICU 住院时间(WMD=1.14,95%CI [-0.45, 2.72])、总住院时间(WMD=0.11,95%CI [-1.02, 1.23])或不良事件发生率(OR=1.02,95%CI [0.79, 1.31]),但显著降低了插管率(OR=0.72,95%CI [0.60, 0.86])。仅接受高流量鼻导管的患者亚组分析也得到了类似结果(死亡率:OR=0.86,95%CI [0.70, 1.05];插管率:OR=0.69,95%CI [0.58, 0.83])。8 项 RCT 均为高质量证据,保证了荟萃分析结果的可靠性。
清醒俯卧位应用于 COVID-19 所致 AHRF 非插管患者是安全可行的,可显著降低插管率。需要进一步研究以探索清醒俯卧位的标准化实施策略。
CRD42023394113。